Investing in mRNA Technologies
David Maza, Managing Director and Head of Product at Direxion, joins Cheddar News to discuss the evolution of mRNA technologies, future applications of this tech including fighting Lyme disease and HIV, and what this all means for investors.
More Videos
Appian CEO on AI’s Next Phase: From Hype to Real-World Results
AI is entering a new phase as enterprises move beyond experimentation and demand measurable returns. Appian CEO Matt Calkins discusses what comes next.
Why This 111-Year-Old Steel Company Is Making a $2.5 Billion Bet on Construction
Commercial Metals CEO Peter Matt reveals how a $2.5B acquisition spree is transforming the 111-year-old steelmaker into a construction solutions powerhouse.
What Amazon, Apple, Microsoft, Meta, and Alphabet Just Told Investors
Angelo Zino, Senior Vice President and Technology Equity Research Analyst at CFRA, breaks down Big Tech earnings, AI spending, and what's next for the Mag 7.
How Phantom Space Plans to Disrupt the Commercial Space Race
Jim Cantrell, Co-Founder and CEO of Phantom Space, explains how the company is working to make rocket launches faster, cheaper, and more scalable.
Meta and Microsoft Just Sent a Big AI Message to Investors
Big Tech is pouring billions into AI. Ray Wang, CEO of Constellation Research, explains what Meta and Microsoft's earnings reveal about those investments.
Can NYC Finally Cool Its Subway?
Why is the NYC subway platform so hot? One rider built his own sensor network to find out. We explore the geothermal fix the MTA is piloting right now.
